PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
 
Sci Rep. 2017; 7: 45249.
Published online 2017 March 24. doi:  10.1038/srep45249
PMCID: PMC5365036

Corrigendum: Long term outcome of Aldosteronism after target treatments

Scientific Reports 6: Article number: 32103; published online: September 02 2016; updated: March 24 201710.1038/srep32103 [Cross Ref]

The original version of this Article contained an error in the Abstract.

“While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.

now reads:

“While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.

This error has now been corrected in the PDF and HTML versions of the Article.


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group